Who are Intravenous thrombolysis plus tirofiban's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-thrombolysis-plus-tirofiban.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intravenous thrombolysis plus tirofiban — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous thrombolysis plus tirofiban (Intravenous thrombolysis plus tirofiban) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent + Antiplatelet agent (combination therapy). Area: Cardiovascular.

phase 3 Fibrinolytic agent + Antiplatelet agent (combination therapy) Fibrin (thrombolytic component); GPIIb/IIIa receptor (tirofiban component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous thrombolysis plus tirofiban (Intravenous thrombolysis plus tirofiban) — The First Affiliated Hospital of University of Science and Technology of China. This combination uses intravenous thrombolysis to dissolve blood clots while tirofiban inhibits platelet aggregation to prevent clot reformation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous thrombolysis plus tirofiban TARGET	Intravenous thrombolysis plus tirofiban	The First Affiliated Hospital of University of Science and Technology of China	phase 3	Fibrinolytic agent + Antiplatelet agent (combination therapy)	Fibrin (thrombolytic component); GPIIb/IIIa receptor (tirofiban component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent + Antiplatelet agent (combination therapy) class)

The First Affiliated Hospital of University of Science and Technology of China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous thrombolysis plus tirofiban — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-thrombolysis-plus-tirofiban. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab